Clinical Trial

A Study of Single Dose of LP-003 in Healthy Adult Subjects

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy subjects.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-17; most recent amendment 2025-12-11.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-12-11
Trial Details
NCT Number NCT06604949
Lead Sponsor Longbio Pharma
Conditions Chronic Spontaneous Urticaria
Enrollment 12 participants
Start Date 2024-10-23
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-18